The FDA has granted accelerated approval to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of locally advanced or metastatic urothelial cancer in patients previously treated with a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor.